Renalytix Ai Stock Today
| RNLX Stock | USD 0.15 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 86
|
Renalytix is trading at 0.15 as of the 3rd of December 2024; that is No Change since the beginning of the trading day. The stock's open price was 0.15. Renalytix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Renalytix AI are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of November 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 17th of July 2020 | Category Healthcare | Classification Health Care |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York. Renalytix operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. The company has 82.96 M outstanding shares of which 378.92 K shares are at this time shorted by private and institutional investors with about 0.39 trading days to cover. More on Renalytix AI
Moving against Renalytix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Renalytix Stock Highlights
| Business Concentration | Health Care Technology, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Technology, Health Information Services, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRenalytix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Renalytix's financial leverage. It provides some insight into what part of Renalytix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Renalytix AI (RNLX) is traded on NASDAQ Exchange in USA and employs 9 people. Renalytix is listed under Health Care Technology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.55 M. Renalytix AI conducts business under Health Care Technology sector and is part of Health Care industry. The entity has 82.96 M outstanding shares of which 378.92 K shares are at this time shorted by private and institutional investors with about 0.39 trading days to cover.
Renalytix AI currently holds about 32.36 M in cash with (30.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Renalytix Probability Of Bankruptcy
Ownership AllocationRenalytix owns a total of 82.96 Million outstanding shares. Renalytix holds 4.51 pct. of its outstanding shares held by insiders and 4.13 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Renalytix Ownership Details
Renalytix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Cvi Holdings Llc | 2024-06-30 | 38.3 K | |
| Xtx Topco Ltd | 2024-09-30 | 20.2 K | |
| Lpl Financial Corp | 2024-09-30 | 18.4 K | |
| Baader Bank Inc | 2024-09-30 | 15 K | |
| Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 14.5 K | |
| Virtu Financial Llc | 2024-06-30 | 12.5 K | |
| Ironwood Investment Counsel, Llc | 2024-09-30 | 12 K | |
| Cim, Llc | 2024-06-30 | 12 K | |
| Jane Street Group Llc | 2024-06-30 | 11.9 K | |
| Pinnacle Associates Inc | 2024-09-30 | 846.5 K | |
| Easterly Investment Partners. | 2024-09-30 | 555 K |
Renalytix AI Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Renalytix market risk premium is the additional return an investor will receive from holding Renalytix long position in a well-diversified portfolio.
| Mean Deviation | 4.95 | |||
| Standard Deviation | 6.43 | |||
| Variance | 41.32 | |||
| Risk Adjusted Performance | (0.10) |
Renalytix Stock Against Markets
Renalytix Corporate Management
| Oliver III | Chief Officer | Profile | |
| Jean Casner | VP Officer | Profile | |
| Baljit Singh | Head Operations | Profile | |
| Howard Doran | Chief Officer | Profile | |
| Salim FCA | Company Secretary | Profile | |
| Fergus Fleming | Chief Officer | Profile | |
| Andria ParksHerrera | VP Marketing | Profile |
Additional Tools for Renalytix Stock Analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.